Aquestive Therapeutics, Inc. (AQST)
5.34
-0.01
(-0.19%)
USD |
NASDAQ |
Sep 04, 16:00
5.34
0.00 (0.00%)
After-Hours: 20:00
Aquestive Therapeutics Research and Development Expense (Quarterly) : 3.962M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.962M |
| March 31, 2026 | 4.204M |
| December 31, 2025 | 3.196M |
| September 30, 2025 | 4.53M |
| June 30, 2025 | 4.105M |
| March 31, 2025 | 5.361M |
| December 31, 2024 | 4.917M |
| September 30, 2024 | 5.269M |
| June 30, 2024 | 4.162M |
| March 31, 2024 | 5.932M |
| December 31, 2023 | 2.888M |
| September 30, 2023 | 3.196M |
| June 30, 2023 | 3.473M |
| March 31, 2023 | 3.547M |
| December 31, 2022 | 4.241M |
| September 30, 2022 | 3.232M |
| June 30, 2022 | 5.198M |
| March 31, 2022 | 4.773M |
| December 31, 2021 | 4.40M |
| Date | Value |
|---|---|
| September 30, 2021 | 4.726M |
| June 30, 2021 | 4.262M |
| March 31, 2021 | 3.659M |
| December 31, 2020 | 4.425M |
| September 30, 2020 | 7.26M |
| June 30, 2020 | 3.847M |
| March 31, 2020 | 4.354M |
| December 31, 2019 | 3.057M |
| September 30, 2019 | 5.063M |
| June 30, 2019 | 8.151M |
| March 31, 2019 | 4.303M |
| December 31, 2018 | 5.683M |
| September 30, 2018 | 4.534M |
| June 30, 2018 | 7.994M |
| March 31, 2018 | 4.901M |
| December 31, 2017 | 6.271M |
| September 30, 2017 | 5.684M |
| June 30, 2017 | 4.837M |
| March 31, 2017 | 5.343M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | 0.00 |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |
| Johnson & Johnson | 3.603B |